Is time wasted?.. Corona vaccines face an "unexpected" problem

In light of the feverish global race to control the Corona epidemic that sparked human terror, it seems that the countries that are running a race to produce a vaccine against "Covid 19" face an unexpected problem.

According to the "Boy Genius Report" website, which specializes in scientific news, experts will face the problem of "a shortage of patients" who will undergo clinical trials in the final stages of the vaccine.

He added: "It was initially planned that the final stages of vaccine development would coincide with the presence of a large number of patients, and thus extensive testing. The problem now is that the number of patients is shrinking day by day."

In this regard, researchers from the University of " Oxford " expected their vaccine to be ready in the month of September, but the current data indicate the possibility of delaying it.

Oxford will vaccinate 10,000 volunteers during the next stage, half of whom will receive the candidate vaccine and the other half will receive a placebo.

But if there are not enough patients, researchers may not be able to tell if the vaccine is effective in preventing infection.

On the other hand, they will still be able to study the immune response, search for antibodies, and assess vaccine safety.

However, "Boy Genius Report," this data would not be sufficient to produce the final results for approval of use and distribution.

China's position

China faces  the same hurdle, at a time when it is testing 4 vaccines against "Covid 19", but the authorities are considering moving forward with the use of vaccines by the end of the year, even if the tests are not completed.

Gao Fu, head of the China Centers for Disease Control, said potential vaccines could be given to specific groups in an emergency , even if the trials were not complete.

He added: "The national immunization program pays close attention and studies groups of people and the type of cases that can benefit from the vaccine ."

He continued: "I think that we will decide based on the cases before us, because we will not be able to follow the usual protocol, otherwise we will waste time."

He concluded by saying: "These vaccines will not be available to the public but to special cases. Over time, special cases may become common to the general public."